Principle Wealth Partners LLC Buys 73 Shares of Eli Lilly and Company (NYSE:LLY)

Principle Wealth Partners LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 1.1% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 6,616 shares of the company’s stock after acquiring an additional 73 shares during the quarter. Principle Wealth Partners LLC’s holdings in Eli Lilly and Company were worth $5,465,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Garner Asset Management Corp grew its holdings in shares of Eli Lilly and Company by 2.3% during the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after purchasing an additional 12 shares during the last quarter. Brighton Jones LLC boosted its stake in Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after purchasing an additional 1,730 shares during the period. Revolve Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the last quarter. Orion Capital Management LLC raised its holdings in shares of Eli Lilly and Company by 2.5% during the 4th quarter. Orion Capital Management LLC now owns 1,610 shares of the company’s stock valued at $1,243,000 after buying an additional 40 shares in the last quarter. Finally, Bank Pictet & Cie Europe AG increased its stake in Eli Lilly and Company by 4.1% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 64,758 shares of the company’s stock worth $49,993,000 after purchasing an additional 2,568 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $2.66 during midday trading on Thursday, reaching $801.55. 642,826 shares of the company’s stock were exchanged, compared to its average volume of 3,757,247. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a market capitalization of $759.66 billion, a PE ratio of 65.11, a price-to-earnings-growth ratio of 1.12 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company’s 50 day simple moving average is $769.41 and its two-hundred day simple moving average is $799.86.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period last year, the business posted $2.58 EPS. Equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company’s payout ratio is 48.82%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent analyst reports. Guggenheim boosted their price target on Eli Lilly and Company from $936.00 to $942.00 and gave the stock a “buy” rating in a research note on Friday, July 11th. Hsbc Global Res lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. Erste Group Bank cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, June 5th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Finally, HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.